Kidney Week

Why Submit to Kidney Week?

• Reach a global audience: Approximately 12,000 leading nephrologists, researchers, industry professionals, and others attend this largest kidney meeting in the world.
• Gain immediate recognition: Attract media attention and scientific interest. All main stage podium presentations will be invited to present at a press-embargoed session.
• Featured high-impact clinical trials in the Opening Plenary.
• More presentation time for high-impact clinical studies.
• Multiple late-breaking abstract (LBA) oral sessions.

Eligibility

Your late-breaking abstract (LBA) submission MUST meet the following criteria for ASN consideration:

• ASN gives preference to Phase 3 and 4 trials that are late-breaking and inform practice - either positive or negative outcomes.
• We also welcome:
  • Exceptional Phase 2 trials with novel prospective interventions,
  • Significant secondary data analysis of previously presented or published RCTs, and
  • Practice-changing observational studies or registries (with preference to multicenter studies with a large sample size).
• Your data has not been and will not be presented at a United States or international meeting before presentation at Kidney Week.
• Your data has not been and will not be published in any form (including preprint servers) before presentation at Kidney Week.
• ASN has adopted the criteria recommended by the International Committee of Medical Journal Editors (ICMJE) in the Recommendations for the Conduct, Reporting, Editing and Publication of Scholarly Work in Medical Journals: "authorship be based on...1. Substantial contributions to the conception or design of the work; or the acquisition, analysis, or interpretation of data for the work; AND 2. Drafting the work or reviewing it critically for important intellectual content; AND 3. Final approval of the version to be published; AND 4. Agreement to be accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved." For your LBA submission:
  • ALL authors must be added to the abstract at the time of submission.
  • ALL authors must have full access to all study data and statistical analyses of the data. If that is not the case, the abstract may be rejected or retracted.
  • Based on the above ICMJE criteria for authorship, artificial intelligence (AI) tools, such as ChatGPT, do not qualify for authorship.
• The Submitter has the authority to submit the LBA and transfer copyright on behalf of the co-authors and company sponsors.
• All research and studies in submitted abstracts must comply with the WMA Declaration of Helsinki, the Declaration of Istanbul on Organ Trafficking and Transplant Tourism, and the NIH Guide for the Care and Use of Laboratory Animals.
• If AI tools, such as ChatGPT "are used to create content or assist with writing or manuscript preparation, authors must take responsibility for the integrity of the content generated by these tools. Authors should report the use of artificial intelligence, language models, machine learning, or similar technologies to create content or assist with writing or editing of manuscripts in the Acknowledgment or Methods section if this is part of formal research design or methods…This should include a description of the content that was created or edited and the name of the language model or tool, version and extension numbers, manufacturer, date(s) of use, and confirmation that the authors take responsibility for the integrity of the content generated. (Note: this does not include basic tools for checking grammar, spelling, references, etc.)" [JAMA Network Authorship Criteria and Contributions]
• "The submission and publication of images created by artificial intelligence, machine learning tools, or similar technologies is discouraged, unless part of formal research design or methods, and is not permitted without clear description of the content that was created and the name of the model or tool, version and extension numbers, and manufacturer. Authors must take responsibility for the integrity of the content generated by these models and tools." [JAMA Network Statistical Methods and Data Presentation]

Important

• Submit as much data as possible. If results are not available at the time of submission, please include the expected date available.
• Do not submit multiple LBAs on the same trial – only one submission per trial is permitted.

Submission Details

1. All LBAs must be submitted online through the ASN abstract submission site by September 2, 2026, 2:00 p.m. EDT for consideration.
2. ALL authors (including co-authors) must create an ASN User Login, if they do not already have one, BEFORE they can be added to an abstract. Please tell your authors to complete this step as soon as possible.
   • Submitter/Submitting Author: This individual serves as the secondary point of contact with ASN regarding the submission. The Submitter is not required to be a contributing author (e.g., administrative assistant or student working with the authors), but must have an ASN User Login with current contact information for submission.
   • Presenting Author: This individual has the primary responsibility for communications with ASN. The Presenting Author is responsible for ensuring that ALL co-authors approve the submission, publication, and potential presentation. The Presenting Author is responsible for ensuring that ALL co-authors who participated in the study and meet the criteria for authorship are listed on the abstract when it is submitted to ASN. The Presenting Author will give the oral or poster presentation, if the submission is accepted, and should feel comfortable presenting and answering questions in English.
   • Co-Authors: The co-authors will be listed in the order provided during submission.
3. An LBA submission may contain a maximum of 2,500 characters. The total character count includes characters and spaces in the following fields: Title, Body, Figures (up to 2), Table (up to 1). Figure count is determined by image height but will not exceed 560 characters. Because image height cannot be calculated manually, we recommend uploading, editing, and replacing figures in the submission until an acceptable quality : character ratio is reached. Table count is 50 characters per row. For complex tables and in situations where control over formatting is desired, we recommend uploading the table as a figure.
4. The LBA submission may be completed on the first visit to the submission site or may be saved and completed at a later time. An LBA may be submitted and paid for, then returned to draft, edited, and resubmitted for no additional fee, by September 2, 2026, at 2:00 p.m. EDT.
5. There is no limit to the number of abstracts that an individual may submit. However, there is a $100 nonrefundable processing fee per LBA submission. The processing fee must be paid at the time of submission by credit card (American Express, MasterCard, or VISA).
6. Upon LBA submission, ALL authors agree to all copyright transfer terms and the ASN embargo policy.
7. Changes: It is important that the Submitter checks the LBA data carefully before submission. For submitted LBAs needing changes through September 2, 2026, at 2:00 p.m. EDT, the Submitter can make changes directly in the abstract submission site. After September 2, for submissions needing MINIMAL changes, the Submitter or Presenting Author can email kidneyweek@asn-online.org with the abstract number in the subject line and the ASN Abstract Change Form attached. Change requests will be handled on a case-by-case basis; ASN may not be able to accommodate all requests. Minimal changes include author additions and typos (if the total character limit permits), but NOT replacement of text, table, and figures.
8. Withdrawals: The Presenting Author can request LBA withdrawal through September 30, 2026, by emailing kidneyweek@asn-online.org. Please note the abstract number in the email subject line and the Presenting Author's name in the email body. The $100 processing fee is nonrefundable. After September 30, withdrawal requests will be accepted on a case-by-case basis, but the LBA may still appear in meeting publications.

Assignment, Notification, and Presentation

All LBA submissions are peer reviewed by the LBA review committee, and authors' names and institutions are blinded during the review process. LBA submissions can be (1) accepted as an oral abstract, (2) accepted as a poster, or (3) rejected. There is no publication-only option for LBA submissions.

Accepted LBAs will be assigned to one of the following:

• Opening Plenary: High-impact clinical trials may be featured in the Opening Plenary on Thursday, October 22, 8:00-9:30 a.m. MDT. The session will be recorded for later viewing.
• High-Impact Clinical Trials Oral Sessions: These sessions will be held in the plenary room on Friday, October 23, 10:30 a.m. - 12:30 p.m. MDT and on Saturday, October 24, 10:30 a.m. - 12:30 p.m. MDT. The sessions will be recorded for later viewing.
• Late-Breaking Research Oral Sessions: These sessions will be held on Thursday, October 22, Friday, October 23, and Saturday, October 24, 4:30-6:00 p.m. MDT. The sessions will be recorded for later viewing.
• Late-Breaking Posters: LBA posters will be presented in the exhibit hall on Thursday, October 22, 9:30 a.m. - 2:30 p.m. MDT. If accepted for poster presentation, the Presenting Author must be available at the poster board at 10:00 a.m. - 12:00 p.m. MDT for presentation and discussion. Poster presenters are encouraged to submit an ePoster to complement their printed poster. LBA ePosters will be available for viewing online starting Thursday, October 22, 10:00 a.m. MDT.

Accepted abstracts will be included in the ASN abstract search tool on Friday, October 2, and on the JASN website on Monday, November 9.

ASN will email notifications to the Presenting Authors and Submitters of all LBA submissions by 11:59 p.m. EDT on September 23, 2026.

It is the responsibility of the Presenting Author to share the notifications with their co-authors. If you are the Presenting Author and have not received your notification by October 1, please email kidneyweek@asn-online.org and note the abstract number in the email subject line and the Presenting Author's name in the email body.

The Presenting Authors of abstracts accepted for oral or poster presentations must register for the Annual Meeting (fees apply) and travel to Denver, CO, to present in-person.

ASN reserves the right to withdraw any submission for any reason at its discretion.

Confidential Advanced Access

All abstracts submitted in connection with Kidney Week are disclosed to ASN's peer review committee, employees, and contractors as necessary. Although ASN and its employees or contractors cannot guarantee the confidentiality of submitted abstracts, every effort will be made to ensure confidentiality of submitted material.

Simultaneous Publication

Simultaneous publication of LBAs is acceptable and encouraged as long as the embargo policies of ASN and the involved journals are coordinated. If an LBA has been submitted to and accepted for publication, the Presenting Author is responsible for ensuring that the journal editorial team respects the ASN embargo policy. Publication of an LBA, either in print or on a journal website prior to presentation at ASN Kidney Week, violates the ASN embargo policy. If you are interested in simultaneous publication, please notify the journal editorial team, who should then contact ASN Press Officer Christine Feheley at cfeheley@asn-online.org to verify embargo dates/times.

Collaboration with JASN, JAMA, NEJM, Lancet, and Nature/Nature Medicine

ASN is pleased to collaborate with JASN, JAMA, NEJM, Lancet, and Nature/Nature Medicine on Kidney Week LBAs. If your LBA has NOT been accepted for publication and you would like ASN to share it confidentially with these journals for publication consideration, please check the appropriate box during the submission process. Each journal will independently review and contact the Presenting Author directly if interested.

Interested in manuscript tips from these journals? Review their podcast/videos: JASN, JAMA, NEJM, Lancet